HIV-1 Vpu neutralizes the antiviral factor tetherin/BST-2 by binding it and directing its Beta-TrCP2-dependent degradation

Mangeat, Bastien, Gers-Huber, Gustavo, Lehmann, Martin, Zufferey, Madeleine, Luban, Jeremy and Piguet, Vincent 2009. HIV-1 Vpu neutralizes the antiviral factor tetherin/BST-2 by binding it and directing its Beta-TrCP2-dependent degradation. PLoS Pathogens 5 (9) , e1000574. 10.1371/journal.ppat.1000574

Preview

PDF - Published Version Available under License Creative Commons Attribution. Download (770kB) | Preview

Abstract

Host cells impose a broad range of obstacles to the replication of retroviruses. Tetherin (also known as CD317, BST-2 or HM1.24) impedes viral release by retaining newly budded HIV-1 virions on the surface of cells. HIV-1 Vpu efficiently counteracts this restriction. Here, we show that HIV-1 Vpu induces the depletion of tetherin from cells. We demonstrate that this phenomenon correlates with the ability of Vpu to counteract the antiviral activity of both overexpressed and interferon-induced endogenous tetherin. In addition, we show that Vpu co-immunoprecipitates with tetherin and β-TrCP in a tri-molecular complex. This interaction leads to Vpu-mediated proteasomal degradation of tetherin in a β-TrCP2-dependent manner. Accordingly, in conditions where Vpu-β-TrCP2-tetherin interplay was not operative, including cells stably knocked down for β-TrCP2 expression or cells expressing a dominant negative form of β-TrCP, the ability of Vpu to antagonize the antiviral activity of tetherin was severely impaired. Nevertheless, tetherin degradation did not account for the totality of Vpu-mediated counteraction against the antiviral factor, as binding of Vpu to tetherin was sufficient for a partial relief of the restriction. Finally, we show that the mechanism used by Vpu to induce tetherin depletion implicates the cellular ER-associated degradation (ERAD) pathway, which mediates the dislocation of ER membrane proteins into the cytosol for subsequent proteasomal degradation. In conclusion, we show that Vpu interacts with tetherin to direct its β-TrCP2-dependent proteasomal degradation, thereby alleviating the blockade to the release of infectious virions. Identification of tetherin binding to Vpu provides a potential novel target for the development of drugs aimed at inhibiting HIV-1 replication.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine Systems Immunity Research Institute (SIURI)
Subjects:	Q Science > QR Microbiology > QR180 Immunology R Medicine > R Medicine (General)
Publisher:	Public Library of Science
ISSN:	1553-7374
Date of First Compliant Deposit:	30 March 2016
Last Modified:	14 May 2023 20:08
URI:	https://orca.cardiff.ac.uk/id/eprint/37362

Citation Data

Cited 235 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item